Posted by Michael Wonder on 24 Jun 2016
NICE publishes appraisal consultation for osimertinib mesylate (Tagrisso) for patients with non-small-cell lung cancer
24 June 2016 - NICE has published an appraisal consultation for AstraZeneca's Tagrisso.
Osimertinib mesylate is not recommended within its marketing authorisation for treating locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small-cell lung cancer in adults.
Closing date for comments on the consultation document is 14 July 2016. The second appraisal committee meeting will nbe held on 27 July 2016.
For more details, go to: View NICE Appraisal Consultation Document
